AI-generated research brief — verify at source
Dapagliflozin Shows No Significant Renal or Hematologic Benefit in Lupus Nephritis RCT
In a randomized, double-blind, placebo-controlled trial of 79 adults with lupus nephritis, dapagliflozin produced a numerical reduction in proteinuria over 12 months compared with placebo, but this difference did not achieve statistical significance after adjustment for baseline characteristics and background immunosuppressive therapy. No significant effects were detected for kidney function, eGFR slope, or any hematologic parameter, leaving the question of SGLT2 inhibitor benefit in this population unresolved.
What Was Studied
The trial investigated whether adding dapagliflozin 10 mg/day to standard immunosuppressive therapy could reduce proteinuria and preserve kidney function in adults with biopsy-proven lupus nephritis — a condition that remains a leading cause of chronic kidney disease and end-stage renal disease despite existing treatments. Secondary interest focused on hematologic effects, including hemoglobin, erythropoietin, hepcidin, ferritin, and transferrin saturation, given prior observations that SGLT2 inhibitors may raise hemoglobin in other chronic kidney disease populations.
How It Was Studied
This was a randomized, double-blind, placebo-controlled trial enrolling 79 adult patients with biopsy-confirmed lupus nephritis and an estimated glomerular filtration rate (eGFR) above 30 ml/min/1.73 m². Participants were assigned to receive either dapagliflozin 10 mg/day (n = 38) or matched placebo (n = 41) for 12 months, both groups continuing their background immunosuppressive regimens. The primary endpoint was the percentage change in 24-hour urinary protein excretion from baseline to 12 months, analyzed using analysis of covariance (ANCOVA) with adjustment for baseline values, age, and background therapy. Sensitivity analyses on log-transformed proteinuria and adjusted eGFR slope analyses were also performed.
What Was Observed
- Proteinuria — primary endpoint, not significant: Dapagliflozin was associated with a directional reduction in 24-hour urinary protein excretion compared with placebo at 12 months, but this numerical difference did not reach statistical significance in either the primary ANCOVA analysis or the log-transformed sensitivity analyses. The absence of a significant treatment effect was consistent across analytical approaches.
- Kidney function — no significant change: Neither eGFR at 12 months nor the rate of eGFR decline over the treatment period (eGFR slope) differed significantly between the dapagliflozin and placebo groups, indicating that dapagliflozin did not meaningfully alter the trajectory of kidney function in this cohort.
- Hematologic parameters — no significant effect: Assessments of hemoglobin, erythropoietin, hepcidin, ferritin, and transferrin saturation at baseline and 12 months revealed no statistically significant differences between treatment arms, suggesting that the hemoglobin-elevating signal reported in other CKD populations was not reproduced in this lupus nephritis sample.
Why This Matters
Lupus nephritis continues to cause serious kidney damage despite advances in immunosuppressive care, and identifying adjunctive therapies that offer additional renoprotection is an active clinical need. SGLT2 inhibitors have demonstrated benefit in both diabetic and non-diabetic chronic kidney disease, and prior associations with increased hemoglobin raised interest in their use in immune-mediated glomerulopathies. This trial provides the first randomized controlled data specifically in lupus nephritis, and its neutral results raise important questions about whether the mechanisms underlying SGLT2 inhibitor benefit in other kidney diseases translate to this immune-driven condition — a distinction with direct implications for how future studies in this population should be designed.
How to Read This Result
Given the small sample size of 79 participants and a trial likely underpowered to detect a clinically meaningful treatment effect, the neutral result cannot be interpreted as definitive evidence of no benefit — the numerical trend in proteinuria reduction remains a candidate signal that adequately powered, longer-duration trials would be needed to evaluate reliably.
Limitations
The trial enrolled only 79 participants across two arms, making it substantially underpowered to detect modest but clinically relevant treatment differences. A 12-month follow-up period may also be insufficient to capture meaningful changes in kidney function trajectories in a disease as heterogeneous as lupus nephritis. The trial was retrospectively registered, which limits some aspects of transparency regarding pre-specified hypotheses. Taken together, these constraints mean the findings must be regarded as preliminary, and replication in larger, prospectively registered, longer-duration multicenter studies is necessary before firm conclusions can be drawn.